Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls

References

• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356.
   PubMed Web of Science ®Google Scholar
• Long GV, Eroglu Z, Infante J, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol. 2018;36(7):667–673.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480–1492.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Hamid O, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36(17):1668–1674.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–1835.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Robert C, Suciu S. Adjuvant pembrolizumab in resected stage III melanoma. N Engl J Med. 2018;379(6):593–595.
   PubMed Web of Science ®Google Scholar
• Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948–960.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
   PubMed Web of Science ®Google Scholar
• Revicki DA, van den Eertwegh AJ, Lorigan P, et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes. 2012;10(1):66.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Larkin J, Wolchok J, et al. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017;82:80–91.
   PubMed Web of Science ®Google Scholar
• Shuk E, Shoushtari AN, Luke J, et al. Patient perspectives on ipilimumab across the melanoma treatment trajectory. Support Care Cancer. 2017;25(7):2155–2167.
   PubMed Web of Science ®Google Scholar
• Cheung WY, White MK, Bayliss MS, et al. Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada. Support Care Cancer. 2018;26(6):1985–1991.
   PubMed Web of Science ®Google Scholar
• Cheung WY, Bayliss MS, White MK, et al. Humanistic burden of disease for patients with advanced melanoma in Canada. Support Care Cancer. 2018;26(6):1985–1991.
   PubMed Web of Science ®Google Scholar
• Rogiers AD, Ben Salama L, et al. Psychosocial outcome and health-related quality of life (HRQoL) in advanced melanoma survivors. Orlando (FL): Cancer Survivorship Symposium Orlando; 2018.
   Google Scholar
• Rogiers A, Boekhout A, Schwarze JK, et al. Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors. J Oncol. 2019;2019:5269062.
   PubMed Web of Science ®Google Scholar
• Schadendorf DL, Wolchok J, et al. Patient-reported quality of life of patients with advanced Melnoma in a phase III study of nivolumab with or without ipilimumab versus ipilimumab alone: 4-year data from check mate 067. American Society of Clinical Oncology, Annual Meeting; Orleando; May 31–June 4, 2019.
   Google Scholar
• van de Poll-Franse LV, Horevoorts N, van Eenbergen M, et al. The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer. 2011;47(14):2188–2194.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Fossa SD, Bjordal K, et al. Test/retest study of the European organization for research and treatment of cancer core quality-of-life questionnaire. J Clin Oncol. 1995;13(5):1249–1254.
   PubMed Web of Science ®Google Scholar
• Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for determination of sample size and interpretation of the European organization for the research and treatment of cancer quality of life questionnaire core 30. J Clin Oncol. 2011;29(1):89–96.
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–144.
   PubMed Web of Science ®Google Scholar
• Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosomat Res. 1995;39(3):315–325.
   PubMed Web of Science ®Google Scholar
• Purcell A, Fleming J, Bennett S, et al. Determining the minimal clinically important difference criteria for the Multidimensional Fatigue Inventory in a radiotherapy population. Support Care Cancer. 2010;18(3):307–315.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370.
   PubMed Web of Science ®Google Scholar
• Spinhoven P, Ormel J, Sloekers PP, et al. A validation study of the hospital anxiety and depression scale (HADS) in different groups of Dutch subjects. Psychol Med. 1997;27(2):363–370.
   PubMed Web of Science ®Google Scholar
• Castelli L, Binaschi L, Caldera P, et al. Fast screening of depression in cancer patients: the effectiveness of the HADS. Eur J Cancer Care. 2011;20(4):528–533.
   PubMed Web of Science ®Google Scholar
• Cormier JN, Ross MI, Gershenwald JE, et al. Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire. Cancer. 2008;112(10):2249–2257.
   PubMed Web of Science ®Google Scholar
• Sangha O, Stucki G, Liang MH, et al. The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49(2):156–163.
   PubMed Web of Science ®Google Scholar
• Minton O, Berger A, Barsevick A, et al. Cancer-related fatigue and its impact on functioning. Cancer. 2013;119(11):2124–2130.
   PubMed Web of Science ®Google Scholar
• Koch L, Jansen L, Brenner H, et al. Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors-a systematic review of quantitative studies. Psychooncology. 2013;22(1):1–11.
   PubMed Web of Science ®Google Scholar
• de Ligt KM, Heins M, Verloop J, et al. Patient-reported health problems and healthcare use after treatment for early-stage breast cancer. Breast. 2019;46:4–11.
   PubMed Web of Science ®Google Scholar
• O’Reilly A, Hughes P, Mann J, et al. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Support Care Cancer. 2020;28(2):561–570.
   PubMed Web of Science ®Google Scholar
• Lai-Kwon J, Khoo C, Lo S, et al. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. J Cancer Surviv. 2019;13(4):503–511.
   PubMed Web of Science ®Google Scholar
• Mamoor M, Postow MA, Lavery JA, et al. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. J Immunother Cancer. 2020;8(1):e000260.
   PubMed Web of Science ®Google Scholar
• Westerman MJ, Hak T, Sprangers MA, et al. Listen to their answers! Response behaviour in the measurement of physical and role functioning. Qual Life Res. 2008;17(4):549–558.
   PubMed Web of Science ®Google Scholar
• Friedrich M, Zenger M, Hinz A. Response shift effects of quality of life assessments in breast cancer survivors. Eur J Cancer Care. 2019;28(2):e12979.
   PubMed Web of Science ®Google Scholar
• Bower JE, Meyerowitz BE, Desmond KA, et al. Perceptions of positive meaning and vulnerability following breast cancer: predictors and outcomes among long-term breast cancer survivors. Ann Behav Med. 2005;29(3):236–245.
   PubMed Web of Science ®Google Scholar
• Joly F, Giffard B, Rigal O, et al. Impact of cancer and its treatments on cognitive function: advances in research from the Paris international cognition and cancer task force symposium and update since 2012. J Pain Symptom Manage. 2015;50(6):830–841.
   PubMed Web of Science ®Google Scholar
• McGinnis GJ, Friedman D, Young KH, et al. Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. Oncotarget. 2017;8(6):9155–9173.
   PubMedGoogle Scholar
• McGinnis GJ, Raber J. CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. Immunotherapy. 2017;9(11):929–941.
   PubMed Web of Science ®Google Scholar
• Bartels F, Stronisch T, Farmer K, et al. Neuronal autoantibodies associated with cognitive impairment in melanoma patients. Ann Oncol. 2019;30(5):823–829.
   PubMed Web of Science ®Google Scholar
• Beutel ME, Fischbeck S, Binder H, et al. Depression, anxiety and quality of life in long-term survivors of malignant melanoma: a register-based cohort study. PLoS One. 2015;10(1):e0116440.
   PubMed Web of Science ®Google Scholar
• Gotze H, Friedrich M, Taubenheim S, et al. Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis. Support Care Cancer. 2020;28(1):211–220.
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Ferguson DW, Gill J, et al. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2013;14(8):721–732.
   PubMed Web of Science ®Google Scholar
• van der Aa MA, de Vries E, Hoekstra HJ, et al. Sociodemographic factors and incidence of melanoma in the Netherlands, 1994–2005. Eur J Cancer. 2011;47(7):1056–1060.
   PubMed Web of Science ®Google Scholar
• Singh SD, Ajani UA, Johnson CJ, et al. Association of cutaneous melanoma incidence with area-based socioeconomic indicators-United States, 2004–2006. J Am Acad Dermatol. 2011;65(1):S58–S68.
   PubMed Web of Science ®Google Scholar
• Hillen MA, Medendorp NM, Daams JG, et al. Patient-driven second opinions in oncology: a systematic review. Oncologist. 2017;22(10):1197–1211.
   PubMed Web of Science ®Google Scholar
• Kim JH, Park EC. Impact of socioeconomic status and subjective social class on overall and health-related quality of life. BMC Public Health. 2015;15(1):783.
   PubMed Web of Science ®Google Scholar